HEMLIBRA® now option for those with, without inhibitor (Hemophilia A)

10/04/2018

On October 4, 2018, the FDA approved HEMLIBRA^® for prevention (prophylaxis) of bleeding episodes in adults and children ages newborn and older with Factor VIII deficiency (Hemophilia A) without an inhibitor. In November 2017, the FDA licensed HEMLIBRA^® for use in FVIII deficiency with inhibitors. HEMLIBRA^® works for both patients with and without an inhibitor with FVIII deficiency (Hemophilia A)!

The IHTC has the most experience, knowledge, and expertise with HEMLIBRA^® in Indiana. The IHTC staff have been extensively trained regarding how to dose, prescribe, monitor and administer HEMLIBRA^®. If you have any questions or want information about HEMLIBRA®, call the center at 1-877-CLOTTER.

LEARN MORE ABOUT THE MOST RECENT FDA APPROVAL OF HEMLIBRA^®